Patents by Inventor Amy E. Wilson

Amy E. Wilson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6723552
    Abstract: This invention provides an isolated nucleic acid encoding a human MCH1 receptor, a purified human MCH1 receptor, vectors comprising isolated nucleic acid encoding a human MCH1 receptor, cells comprising such vectors, antibodies directed to a human MCH1 receptor, nucleic acid probes useful for detecting nucleic acid encoding human MCH1 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding human MCH1 receptors, transgenic, nonhuman animals which express DNA encoding a normal or mutant human MCH1 receptor, methods of isolating a human MCH1 receptor, methods of treating an abnormality that is linked to the activity of a human MCH1 receptor, as well as methods of determining binding of compounds to mammalian MCH1 receptors.
    Type: Grant
    Filed: June 20, 2001
    Date of Patent: April 20, 2004
    Assignee: Synaptic Pharmaceutical Corporation
    Inventors: John A. Salon, Thomas M. Laz, Raisa Nagorny, Amy E. Wilson
  • Publication number: 20040038855
    Abstract: This invention provides an isolated nucleic acid encoding a human MCH1 receptor, a purified human MCH1 receptor, vectors comprising isolated nucleic acid encoding a human MCH1 receptor, cells comprising such vectors, antibodies directed to a human MCH1 receptor, nucleic acid probes useful for detecting nucleic acid encoding human MCH1 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding human MCH1 receptors, transgenic, nonhuman animals which express DNA encoding a normal or mutant human MCH1 receptor, methods of isolating a human MCH1 receptor, methods of treating an abnormality that is linked to the activity of a human MCH1 receptor, as well as methods of determining binding of compounds to mammalian MCH1 receptors. This invention further provides a method of treating a subject suffering from urinary incontinence which comprises administering to the subject an amount of an MCH1 antagonist effective to treat the subject's urinary incontinence.
    Type: Application
    Filed: January 14, 2003
    Publication date: February 26, 2004
    Inventors: John A. Salon, Thomas M. Laz, Raisa Nagorny, Amy E. Wilson, Douglas A. Craig
  • Publication number: 20030143670
    Abstract: This invention provides isolated nucleic acids encoding mammalian SNORF44 receptor, purified mammalian SNORF44 receptor, vectors comprising nucleic acid encoding mammalian SNORF44 receptor, cells comprising such vectors, antibodies directed to mammalian SNORF44 receptor, nucleic acid probes useful for detecting nucleic acid encoding mammalian SNORF44 receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding mammalian SNORF44 receptor, transgenic, nonhuman animals which express DNA encoding normal or mutant mammalian SNORF44 receptor, and methods of isolating mammalian SNORF44 receptor. This invention also provides methods of treating an abnormality that is linked to the activity of a mammalian SNORF44 receptor, as well as methods of determining binding of compounds to a mammalian SNORF44 receptor, methods of identifying agonists and antagonists of a SNORF44 receptor, and agonists and antagonists so identified.
    Type: Application
    Filed: February 20, 2002
    Publication date: July 31, 2003
    Inventors: James A. Bonini, Ling-Yan Huang, Amy E. Wilson
  • Publication number: 20030077701
    Abstract: This invention provides an isolated nucleic acid encoding a human MCH1 receptor, a purified human MCH1 receptor, vectors comprising isolated nucleic acid encoding a human MCH1 receptor, cells comprising such vectors, antibodies directed to a human MCH1 receptor, nucleic acid probes useful for detecting nucleic acid encoding human MCH1 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding human MCH1 receptors, transgenic, nonhuman animals which express DNA encoding a normal or mutant human MCH1 receptor, methods of isolating a human MCH1 receptor, methods of treating an abnormality that is linked to the activity of a human MCH1 receptor, as well as methods of determining binding of compounds to mammalian MCH1 receptors.
    Type: Application
    Filed: December 20, 2001
    Publication date: April 24, 2003
    Inventors: Carlos Forray, John A. Salon, Thomas M. Laz, Raisa Nagorny, Amy E. Wilson
  • Publication number: 20020111306
    Abstract: This invention provides an isolated nucleic acid encoding a human MCH1 receptor, a purified human MCH1 receptor, vectors comprising isolated nucleic acid encoding a human MCH1 receptor, cells comprising such vectors, antibodies directed to a human MCH1 receptor, nucleic acid probes useful for detecting nucleic acid encoding human MCH1 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding human MCH1 receptors, transgenic, nonhuman animals which express DNA encoding a normal or mutant human MCH1 receptor, methods of isolating a human MCH1 receptor, methods of treating an abnormality that is linked to the activity of a human MCH1 receptor, as well as methods of determining binding of compounds to mammalian MCH1 receptors.
    Type: Application
    Filed: June 20, 2001
    Publication date: August 15, 2002
    Inventors: John A. Salon, Thomas M. Laz, Raisa Nagorny, Amy E. Wilson
  • Patent number: 6291195
    Abstract: This invention provides an isolated nucleic acid encoding a human MCH1 receptor, a purified human MCH1 receptor, vectors comprising isolated nucleic acid encoding a human MCH1 receptor, cells comprising such vectors, antibodies directed to a human MCH1 receptor, nucleic acid probes useful for detecting nucleic acid encoding human MCH1 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding human MCH1 receptors, transgenic, nonhuman animals which express DNA encoding a normal or mutant human MCH1 receptor, methods of isolating a human MCH1 receptor, methods of treating an abnormality that is linked to the activity of a human MCH1 receptor, as well as methods of determining binding of compounds to mammalian MCH1 receptors.
    Type: Grant
    Filed: January 6, 2000
    Date of Patent: September 18, 2001
    Assignee: Synaptic Pharmaceutical Corporation
    Inventors: John A. Salon, Thomas M. Laz, Raisa Nagorny, Amy E. Wilson
  • Patent number: 6221613
    Abstract: This invention provides an isolated nucleic acid encoding a human MCH1 receptor, a purified human MCH1 receptor, vectors comprising isolated nucleic acid encoding a human MCH1 receptor, cells comprising such vectors, antibodies directed to a human MCH1 receptor, nucleic acid probes useful for detecting nucleic acid encoding human MCH1 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding human MCH1 receptors, transgenic, nonhuman animals which express DNA encoding a normal or mutant human MCH1 receptor, methods of isolating a human MCH1 receptor, methods of treating an abnormality that is linked to the activity of a human MCH1 receptor, as well as methods of determining binding of compounds to mammalian MCH1 receptors.
    Type: Grant
    Filed: December 31, 1998
    Date of Patent: April 24, 2001
    Assignee: Synaptic Pharmaceutical Corporation
    Inventors: John A. Salon, Thomas M. Laz, Raisa Nagorny, Amy E. Wilson
  • Patent number: 6221616
    Abstract: This invention provides an isolated nucleic acid encoding a human MCH1 receptor, a purified human MCH1 receptor, vectors comprising isolated nucleic acid encoding a human MCH1 receptor, cells comprising such vectors, antibodies directed to a human MCH1 receptor, nucleic acid probes useful for detecting nucleic acid encoding human MCH1 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding human MCH1 receptors, transgenic, nonhuman animals which express DNA encoding a normal or mutant human MCH1 receptor, methods of isolating a human MCH1 receptor, methods of treating an abnormality that is linked to the activity of a human MCH1 receptor, as well as methods of determining binding of compounds to mammalian MCH1 receptors.
    Type: Grant
    Filed: January 6, 2000
    Date of Patent: April 24, 2001
    Assignee: Synaptic Pharmaceutical Corporation
    Inventors: John A. Salon, Thomas M. Laz, Raisa Nagorny, Amy E. Wilson